Navigation Links
Atypical protein kinase C stabilizes SRC-3 levels in breast cancer cells
Date:2/28/2008

A new study provides valuable insight into a previously undescribed mechanism that regulates a prominent cancer-associated protein. The research, published by Cell Press in the February 29th issue of Molecular Cell, will enhance understanding of the fundamental processes that contribute to breast cancer.

It is well established that steroid receptor coactivator-3 (SRC-3/AIB1) plays key roles in cell growth, reproduction, metabolism and cytokine signaling, is overexpressed in many cancers and is a major player in tumorigenesis and cancer progression. It is also clear that protein kinases are often overactive in cancers and that distinct patterns of phosphorylation, induced by different signals and different kinases, can play a major role in regulating cancer-associated proteins, including SRC-3.

Recently, it was shown that phosphorylation of SRC-3 by specific kinases is associated with increased degradation of SRC-3. However, kinases that stabilize SRC-3 in cancer cells have not yet been reported, explains lead author Dr. Bert OMalley from the Baylor College of Medicine. Dr. OMalley and colleagues examined the interaction between atypical protein kinase C (aPKC), which is overexpressed in many cancers, and SRC-3.

The researchers found that aPKC stabilized cellular SRC-3 protein levels by inducing phosphorylation of a particular region of SRC-3. Specifically, phosphorylation of C-terminal residues induced a conformational change that made SRC-3 more resistant to degradation by the core proteasome. This effect of aPKC required estrogen and estrogen receptor and was not supported by other steroid receptors, suggesting that aPKC-mediated SRC-3 stabilization is a receptor-selective event. These results reveal a mechanism that links aPKC with estrogen-dependent growth and tumorigenesis and provide yet another layer of control for regulating levels of the SRC-3 oncogenic protein.

Our data describe a new regulatory mechanism for SRC-3 protein turnover which may play an important role in regulating SRC-3 levels in normal and oncogenic cell growth, offers Dr. OMalley. We propose that when aPKC is overexpressed in cancer cells, the consequence is increased SRC-3 function and powerful enhancement of estrogen-receptor target gene transcription and promotion of estrogen-dependent cell growth in cancer cells such as breast.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
4. Emory researchers identify signaling protein for multiple myeloma
5. Human C-reactive protein regulates myeloma tumor cell growth and survival
6. Lowering Blood Protein Wont Help Kidney Patients
7. Blood protein detects lung cancer, even at earliest stage
8. Natural Protein Could Help Spot, Treat Liver Cancer
9. Heat shock proteins are co-opted for cancer
10. How adhesive protein causes malaria
11. Loss of gene leads to protein splicing and buildup of toxic proteins in neurons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... of ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and ... may have been used to remove decayed dental matter, and that teeth were then ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. Shah, ... is a benign bony lump located on the forehead usually attributed to a facial ... sight and pain. Dr. Shah has discovered an approach that is minimally invasive. He ...
(Date:4/21/2017)... ... 2017 , ... Dudnyk has announced the launch of its new brand identity, ... potential of specialty and orphan brands can only be achieved when the needs and ... Effect is at the heart of a true partnership between our agency and our ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
Breaking Medicine Technology: